Concepedia

Jason Rusk

JR

Statistics

Publications

6

Citations

516

H-Index

6

Active since

2002

Affiliations

Gilead Sciences (United States)(Current)

Jason Rusk is an author at Gilead Sciences (United States) specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

2002–2011

6

Publications

6

Effects of Smoking on the Pharmacokinetics of Erlotinib

Marta Hamilton, Julie Wolf, Jason Rusk et al. · Clinical Cancer Research · 2006 · 311 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

Michael V. Seiden, Franco M. Muggia, Allan Astrow et al. · Gynecologic Oncology · 2004 · 85 citations

Medicine, Oncology, Pharmacology +14

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Fairooz F. Kabbinavar, Tim Eisen et al. · Journal of Clinical Oncology · 2011 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib

Marta Hamilton, Julie Wolf, Denni M. Zborowski et al. · 2005 · 17 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma

Ann Mohrbacher, Stephanie A. Gregory, Don A. Gabriel et al. · Cancer · 2002 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 6